

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-00	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO MXI-101CPACN	SERIAL NO. 10/627307
PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT van de Winkel, J.G.J.	
FILING DATE July 25, 2003		GROUP 3763 1644	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PV	A1	4,470,925	09/84	Auditore-Hargreaves	200	142 D	
	A2	4,676,980	06/87	Segal et al.	424	05	
	A3	4,954,617	09/90	Fanger et al.	530	387	
	A4	5,635,600	06/97	Fanger et al.	530	387.3	
V	A5	5,767,106	06/98	Turley et al.	514	54	

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
PV	A6	WO 91/00360	01/91	PCT			
	A7	WO 91/03493	03/91	PCT			
	A8	WO 91/05871	05/91	PCT			
	A9	WO 92/05793	04/92	PCT			
	A10	WO 94/10332	05/94	PCT			
V	A11	WO 95/09002	04/95	PCT			

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

PV	A12	Andrews, R. et al. (1986) "The L4F3 Antigen is Expressed by Unipotent and Multipotent Colony-Forming Cells but Not by Their Precursors", <i>Blood</i> , <u>68</u> (5):1030-1035;
	A13	Ball, E. et al. (1992) "Initial Trial of Bispecific Antibody-Mediated Immunotherapy of CD15-Bearing Tumors: Cytotoxicity of Human Tumor Cells Using a Bispecific Antibody Comprised of Anti-CD15 (MoAb PM81) and Anti-CD64/FcγRI (MoAb 32)" <i>Journal of Hematotherapy</i> <u>1</u> :85-94;
	A14	Brennan, M. et al. (1985) "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G ₁ Fragments" <i>Science</i> <u>229</u> : 81-83;
	A15	Cutitta, F. et al. (1981) "Monoclonal Antibodies that Demonstrate Specificity for Several Types of Human Lung Cancer", <i>PNAS</i> , <u>78</u> (7):4591-4595;
	A16	Graziano, R. et al. (1995) "Construction and Characterization of a Humanized Anti-Gamma-Ig Receptor Type I (FcγRI) Monoclonal Antibody" <i>The Journal of Immunology</i> , <u>155</u> (10):4996-5002;
	A17	Guyre, P. et al. (1989) "Monoclonal Antibodies that Bind to Distinct Epitopes on FcγRI are Able to Trigger Receptor Function" <i>The Journal of Immunology</i> <u>143</u> (5):1650-1655;
	A18	Guyre, P. et al. (1983) "Recombinant Immune Interferon Increases Immunoglobulin G Fc Receptors on Cultured Human Mononuclear Phagocytes" <i>Journal of Clinical Investigation</i> <u>72</u> :393-397;
V	A19	Harris, W. et al. (1993) "Therapeutic Antibodies - The Coming of Age" <i>Tibtech</i> <u>11</u> :42-44;
Examiner		/F. Pierre Vandervegt/
Date Considered		06/21/2006
EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO MXI-101CPACN	SERIAL NO. 10/627307
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT van de Winkel, J.G.J.	
		FILING DATE July 25, 2003	GROUP 3763 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
PV	B1	WO 95/09917	04/95	PCT				
	B2	WO 96/40789	12/96	PCT				
	B3	WO 97/07218	02/97	PCT				
V	B4	WO 98/09647	03/98	PCT				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

<div style="text-align: center;"> </div>	B5	Heijnen, I.A.F.M. and van de Winkel, J.G.J. (1995) "A Human FcγRI/CD64 Transgenic Model for In Vivo Analysis of (Bispecific) Antibody Therapeutics" <i>Journal of Hematotherapy</i> 4:351-356;	
	B6	Hird, V. et al. (1990) "Immunotherapy with Monoclonal Antibodies", <i>Genes and Cancer</i> , Edited by D. Carney and K. Sikora, Chapter 17, pp. 183-189;	
	B7	Kaminski, N.E. et al. (1986) "Target Ricin by Coupling to an Anti-macrophage Monoclonal Antibody" <i>Journal of Immunopharmacology</i> 8(1):15-37;	
	B8	Karpovsky, B. et al. (1984) "Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fcγ Receptor Antibodies" <i>Journal of Experimental Medicine</i> 160:1686-1701;	
	B9	Liu, M. et al. (1985) "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes" <i>PNAS</i> 82:8648-8652;	
	B10	Schlom, J. (1991) "Monoclonal Antibodies: They're More and Less Than You Think", <i>Molecular Foundations of Biology</i> Edited by Williams and Wilkins, Chapter 6, pp. 95-134;	
	B11	Seaver, S. (1994) "Monoclonal Antibodies in Industry: More Difficult Than Originally Thought" <i>Genetic Engineering</i> 14(14):10 & 21;	
	B12	Shen, L. et al. (1986) "Heteroantibody-Mediated Cytotoxicity: Antibody to the High Affinity Fc Receptor for IgG Mediates Cytotoxicity by Human Monocytes that is Enhanced by Interferon-γ and is not Blocked by Human IgG", <i>The Journal of Immunology</i> 137 (11):3378-3382;	
	B13	Valerius, T. et al. (December 1997) "FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy" <i>Blood</i> 90(11):4485-4492;	
	B14	Valerius, T. et al. (1997) "HLA Class II Antibodies Recruit G-CSF Activated Neutrophils for Treatment of B Cell Malignancies" <i>Leukemia and Lymphoma</i> 26:261-269;	
	B15	van de Winkel, J.G.J. et al. (1987) "Characterization of Two Fc Receptors for Mouse Immunoglobulins on Human Monocytes and Cell Lines" <i>Scand. J. Immunol.</i> 26:663-672;	
	B16	van der Pol, W.-Ludo and van de Winkel, J.G.J. (1998) "IgG Receptor Polymorphisms: Risk Factors for Disease" <i>Immunogenetics</i> 48:222-232;	
	Examiner		/F. Pierre Vandervegt/
	Date Considered		06/21/2006
	<p>*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO MXI-101CPACN	SERIAL NO. 10/627307
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT van de Winkel, J.G.J.	
		FILING DATE July 25, 2003	GROUP 3709 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

PV	C1	van Vugt, M.J. et al. (1998) "FcγRII-γ-Chain Complexes Trigger Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) in CD5+ B Cell/Macrophage IIA1.6 Cells" <i>Clin. Exp. Immunol.</i> 113:415-422;
	C2	van Vuuren, A.J.H. et al. (June 1999) "Characterization of the Human Myeloid IgA Fc Receptor I (CD89) Gene in a Cosmid Clone" <i>Immunogenetics</i> 49(6):586-589;
	C3	van Zandbergen, G. et al. (Dec. 1998) "Reduced Binding of Immunoglobulin A (IgA) from Patients with Primary IgA Nephropathy to the Myeloid IgA Fc-receptor, CD89" <i>Nephrol. Dial. Transplant.</i> 13(12):3058-3064;
	C4	Würfle, D. et al. (July 1998) "Evaluating Antibodies for Their Capacity to Induce Cell-mediated Lysis of Malignant B Cells" <i>Cancer Research</i> 58:3051-3058;
	C5	Deo, Y.M. et al. (March 1997) "Clinical Significance of IgG Fc Receptors and FcγR-Directed Immunotherapies" <i>Immunology Today</i> 18(3):127-135;
	C6	Garnett, M.C. et al. (1983) "Preparation and Properties of a Drug-Carrier-Antibody Conjugate Showing Selective Antibody-Directed Cytotoxicity <i>In Vitro</i> " <i>Int. J. Cancer</i> 31:661-670 (1983);
✓	C7	Heijnen, I.A.F.M. et al. (January 1996) "Antigen Targeting to Myeloid-specific Human FcγRI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice" <i>J. Clin. Invest.</i> 97(2):331-338.
Examiner		/F. Pierre Vandervegt/
Date Considered		06/21/2006
*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO MXI-101CPACN	SERIAL NO. 10/627307
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT van de Winkel, J.G.J.	
		FILING DATE July 25, 2003	GROUP 3703 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PV	D1	4,671,958	06/87	Rodwell et al.	424	1.53	
	D2	4,869,903	09/89	Lifson et al.	424	195.45	
	D3	5,026,557	06/91	Estis et al.	424	450	
	D4	5,489,525	02/96	Pastan	435	7.23	
	D5	5,578,706	11/96	Ghetie et al.	530	391.7	
	D6	5,580,715	12/96	McGrath et al.	435	3	
	D7	5,658,568	08/97	Bagshawe et al.	424	134.4	
	D8	5,686,072	11/97	Uhr et al.	424	100.1	
	D9	5,840,840	11/98	Rybak et al.	530	350	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

PV	D10	Bjerke et al. "Fc gamma-receptors in skin and serum from patients with psoriasis, before and after therapy." <i>Acta Derm Venereol Suppl</i> (Stockh). 1994;186:141-2
	D11	Curnow "Clinical experience with CD64-directed immunotherapy. An overview." <i>Cancer Immunol Immunother.</i> 1997 Nov-Dec;45(3-4):210-5
	D12	Ericson et al. "Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes." <i>Br J Haematol.</i> 1996 Mar;92(3):718-24
Examiner		Date Considered
/F. Pierre Vandervegt/		06/21/2006
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		